Summary: Capitainer has launched its U.S. operations with a state-of-the-art lab in Rhode Island to introduce its patented self-sampling technology for plasma, whole blood, and urine.
Takeaways:
- U.S. Expansion: Capitainer’s new Rhode Island lab will enhance commercialization, supporting method development, validations, and partner distribution to accelerate nationwide adoption of self-sampling technology.
- Innovative Product Portfolio: Capitainer’s microsampling devices include CE-marked solutions for dried blood spots and the SEP10 plasma-separation product, with applications in clinical care, decentralized trials, and public health.
- Future Innovations: Capitainer plans to launch a new urine microsampling product in early 2025, further expanding its reach in clinical trials and patient-centric healthcare solutions.
Capitainer announced the launch of its U.S. operations, which will introduce the company’s self-sampling technology for plasma, whole blood, and urine nationwide.
Self-Sampling Technology
The expansion into the United States is a key component of Capitainer’s ambitious growth strategy, the company says. The company’s patented technology enables quantitative, remote blood sampling, in situations where traditional blood sampling at healthcare facilities would typically be required.
The state-of-the-art laboratory in Rhode Island has been established to enhance the upcoming commercialization efforts. The facility will support partners with method development and validations and serve as an initial laboratory supplier for new customers.
“By establishing a U.S. operation, we empower our partners to expand their offerings with Capitainer’s groundbreaking blood sampling products to existing and new customers,” says Christopher Aulin, CEO of Capitainer. “As the demand for blood-based tests increases, our microsampling devices offer a low-cost, user-friendly solution for rapid at-home blood sampling. Our CE marked products have been rigorously tested and proven effective for clinical care, decentralized clinical trials, and public health screening. We believe our blood sampling products can play a vital role in monitoring and safeguarding the health of the American population. With a robust base that includes a laboratory, warehouse, and partners for kitting and distribution, we can accelerate our U.S. sales and operations significantly.”
Capitainer’s Product Portfolio
The product portfolio includes blood sampling products for various volumes of dried blood and the recently launched SEP10, which separates plasma from blood cells—a feature greatly expanding the range of applications. Protection for this product is included in nine patent applications – four of which have already been granted in the U.S.
“Our products are transforming how customers approach blood sampling. Beyond our traditional focus on healthcare and environmental testing, we are witnessing increased interest from partners. involved in clinical trials,” says Donald Chace, laboratory director and principal scientist, for the company. “As decentralized clinical trials become more essential, partners are seeking solutions that enable them to reach more patients, expedite trials, and reduce costs. This is particularly becoming relevant for large clinical studies, for whom travel can be challenging. Our microsampling products for plasma and whole blood present exciting new possibilities and we will present our new urine product in start of 2025.”
